Skip to content
naulon

Not checkedNot checked for notices yet.

Feasibility of repeated using 3D printed applicator in brachytherapy for cervical cancer

ZHAO Xiujuan, ZHONG Mingsong, WU Haiyan and 2 more

陆军军医大学学报 · 2022

doi:10.16016/j.2097-0927.202204057 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Objective To explore the feasibility of repeated use of the same mold in the brachytherapy of cervical cancer by comparing the dosimetry of the 3D-printed vaginal applicator in the pre-plan and actual treatment plan in the brachytherapy of cervical cancer. Methods A total of 10 patients with cervical squamous cell carcinoma who received radical radiotherapy in our hospital from November 2019 to July 2020 were reruited in this study. All patients received concurrent radiotherapy and chemotherapy combined with 3D printed applicator assisted brachytherapy. Dosimetric parameters, including CT scan frequency, high risk clinical target area (HR-CTV) volume and D90 dose, conformity index (CI), Dose (D2cc, the absorbed dose received by 2 cm3 of OARs) variation in organs at risk (OARs), and short-term efficacy and 2-year survival outcome of local control rates (LCR), disease free survival (DFS) and overall survival (OS) were compared the parameters of 3D printed mold pre-planning and multiple actual treatment plans. Paired samples t test was used to compare the parameters of pre-planning and actual treatment plans. Kaplan-Meier survival analysis was applied to analyze the survival outcomes of the patients. Results Ten 3D printing applicators were designed, and a total of 84 CT scans and 47 practical treatments were completed. Only the target volume and CI of the first actual treatment plan were similar to those of the pre-plan, but the difference was not statistically significant (P>0.05). The more times of close treatment, the smaller HR-CTV volume was and the better CI of target area was. Both HR-CTV D90 dose and the OARs dose met clinical requirement. During the median follow-up of 23.5 months, the 2-year LCR, DFS and OS were 100%, 90% and 80%, respectively. Conclusion The 3D-printed vaginal applicator can be used repeatedly for brachytherapy of the same cervical cancer patient, but the needle depth needs to be adjusted by CT positioning.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.